OncoMatch/Clinical Trials/NCT07719556
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
Is NCT07719556 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Orelabrutinib and Obinutuzumab for mantle cell lymphoma (mcl).
Treatment: Orelabrutinib · Obinutuzumab · Venetoclax — This study aims to evaluate the safety and efficacy of orelabrutinib (O) in combination with obinutuzumab (G) and short-course venetoclax (V) in patients with treatment-naïve MCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
ECOG performance status 0-2. Patients with ECOG 3 may be enrolled only if the decline in performance status is attributed to the underlying disease and the investigator determines that they may benefit from the treatment
Prior therapy
Lab requirements
Blood counts
absolute neutrophil count > 1.0×10⁹/L or platelet count > 75×10⁹/L, unless cytopenias are considered to be related to bone marrow involvement by lymphoma and deemed recoverable by the investigator
Kidney function
serum creatinine (CRE) ≤ 1.5 × ULN; creatinine clearance ≥ 30 mL/min, calculated using the Cockcroft-Gault formula
Liver function
AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN (in the absence of liver involvement) or ≤ 5 × ULN (in the presence of liver involvement); total bilirubin (TBIL) ≤ ULN
Cardiac function
Left ventricular ejection fraction (LVEF) < 50% [excluded]; uncontrolled congestive heart failure (NYHA Class III or IV); symptomatic coronary artery disease; severe bradycardia (heart rate < 40 bpm) with hypotension, dizziness, or syncope
Adequate bone marrow reserve, defined as: absolute neutrophil count > 1.0×10⁹/L or platelet count > 75×10⁹/L, unless cytopenias are considered to be related to bone marrow involvement by lymphoma and deemed recoverable by the investigator; Hepatic function: AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN (in the absence of liver involvement) or ≤ 5 × ULN (in the presence of liver involvement); total bilirubin (TBIL) ≤ ULN; serum creatinine (CRE) ≤ 1.5 × ULN; Creatinine clearance ≥ 30 mL/min, calculated using the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07719556 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages